Stan

kind of ailment that we might be dealing with as humans, I have a feeling that we might be headed towards quick fix drugs.

Yeah.

So, Barry, okay, I know you have some insight here or some questions.

So, all right, so let's go.

So let me ask this.

It seems to me that there's this whole cadre of variables that we're dealing with here.

So I'll just list out that kind of what's coming to my mind here as everybody's talking.

One is cost.

Just in general about drugs, and I'll back up on this.

Access.

Health insurance, which I can talk about that.

Orphan drugs.

Okay?

In other words, it's one thing, you know, these...

I'll just call them for lack of a better term right now, these fad drugs.

But what about orphan drugs, you know, where people really need them, but their cost is astronomical.

And then the real question underlying all of this is from your perspectives, what does the public need to know?

So let's back up a little bit here.

Let's talk about costs.

I mean, you guys have been in the field, the two of you have been in this field for a while now.